Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III or IV cutaneous malignant melanoma~* HLA-A1 and/or HLA-A2 expression by serologic HLA typing~  * HLA-A2.1 subtype must be confirmed by polymerase chain reaction on genomic DNA obtained from peripheral blood mononuclear cells~* No active CNS metastases by CT scan or MRI~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Karnofsky 60-100%~Life expectancy~* At least 4 months~Hematopoietic~* WBC greater than 2,500/mm\^3~* Neutrophil count greater than 1,000/mm\^3~* Lymphocyte count greater than 700/mm\^3~* Platelet count greater than 75,000/mm\^3~* Hemoglobin greater than 9 g/dL~* No bleeding disorders~Hepatic~* Bilirubin less than 2.0 mg/dL~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal~* Creatinine less than 2.5 mg/dL~Cardiovascular~* No clinically significant heart disease~Pulmonary~* No clinically significant respiratory disease~Immunologic~* No active systemic infection~* No immunodeficiency disease~  * No evidence of HIV-1, HIV-2, or human T-cell lymphotropic virus-1~* No active autoimmune disease including (but not limited to):~  * Lupus erythematosus~ * Autoimmune thyroiditis or uveitis~ * Multiple sclerosis~ * Inflammatory bowel disease~Other~* Stable medical condition~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 1 month after study participation~* No organic brain syndrome or psychiatric illness that would preclude study compliance~* No other concurrent active malignancy~* No other concurrent serious illness that would preclude study treatment~* No contraindication to leukapheresis~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 4 weeks since prior immunotherapy~* No other concurrent immunotherapy~Chemotherapy~* More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas)~* No concurrent chemotherapy~Endocrine therapy~* No concurrent corticosteroids~Radiotherapy~* More than 4 weeks since prior radiotherapy~* No prior radiotherapy to the spleen~* Concurrent palliative radiotherapy allowed~Surgery~* Recovered from prior surgery~* No prior splenectomy~* No prior organ allograft~* Concurrent surgery on selected metastases (e.g., because of pain or local complications such as compression) allowed~Other~* No other concurrent investigational drugs~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).